South Korean industry grapples with new rebate controls
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies in South Korea are having to work out how to comply with tougher controls on the provision of rebates and other promotional activities, which if contravened can now lead to substantial price cuts for individual drugs.